SAN FRANCISCO, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Humacyte, a biotechnology company focused on regenerative medicine, is now facing an investor class action alleging that the company misled investors about the status of its key product and the regulatory compliance of its manufacturing facilities.
Hagens Berman urges investors in Humacyte (NASDAQ: HUMA) who suffered substantial losses to submit your losses now.
Class Period: May 10, 2024 – Oct. 17, 2024
Lead Plaintiff Deadline: Jan. 17, 2025
Visit: www.hbsslaw.com/investor-fraud/huma
Contact the Firm Now: HUMA@hbsslaw.com | 844-916-0895
Humacyte, Inc. (HUMA) Securities Class Action:
The lawsuit claims that Humacyte and certain of its executives failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, the complaint alleges that the company’s Durham, North Carolina facility had significant manufacturing compliance issues, including deficiencies in quality assurance and microbial testing.
The alleged misconduct came to light after the FDA’s inspection of the facility and the subsequent delay in the review of Humacyte’s Biologic License Application (BLA) for its acellular tissue engineered vessel (ATEV). Specifically, on August 9, 2024, the company announced that the FDA would require additional time to complete its review of the BLA. Then, on October 17, 2024, the FDA issued a Form 483 detailing multiple violations at the Durham facility.
Following these revelations, Humacyte’s stock price experienced a significant decline.
These events have prompted shareholder rights firm Hagens Berman to open an investigation into the alleged claims.
“Investors appear to have been harmed by Humacyte’s alleged failure to disclose critical information about its business and operations,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation. “If the allegations are true, we believe that the company’s conduct constitutes a serious violation of securities laws,” said Kathrein.
If you invested in Humacyte or have knowledge that may assist the firm’s investigation, submit your losses now.
If you’d like more information and answers to frequently asked questions about the Humacyte case and our investigation, read more.
Whistleblowers: Persons with non-public information regarding Humacyte should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email HUMA@hbsslaw.com.
About Hagens Berman
Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.
Contact:
Reed Kathrein, 844-916-0895
